14 15 Cell fate decision upon prolonged mitotic arrest induced by microtubule 16 targeting agents depends on the activity of the tumor suppressor and F-17 box protein FBXW7. FBXW7 promotes mitotic cell death and prevents 18 premature escape from mitosis through mitotic slippage. Mitotic 19
INTRODUCTION 35 36
The attachment of a single ubiquitin molecule or a polyubiquitin chain to a 37 eukaryotic protein is an essential signaling event that can profoundly affect 38 the fate of the target protein. For example, the ubiquitin-proteasome system 39 controls protein degradation in a broad array of cellular processes [1] . Cancer 40 cells often contain mutations targeting ubiquitin-mediated proteolysis that lead 41 to tumorigenesis. FBXW7, an F-box protein and substrate receptor for the 42 SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex, acts as a tumor 43 suppressor and is mutated or deleted in a variety of human cancers [2] . 44 FBXW7 exerts its anti-tumor activity through destruction of key oncoproteins, 45
including JUN [3] [4] , MYC [5] [6], Cyclin E [7] [8] [9] and Notch1 [10] [11] . 46
The abundance of F-box proteins including FBXW7 is controlled by 47 ubiquitylation and degradation in an autocatalytic reaction within the SCF 48 complex [12] . FBXW7 autoubiquitylation can be regulated by Glomulin 49 (GLMN), a protein that binds to RBX1 leading to inhibition of SCF activity, 50 thereby increasing FBXW7 protein levels [13] [14] . The only ubiquitin ligase 51 known to date involved in regulating FBXW7 levels in neurons is Parkin. 52
However, this regulation has only been observed for the FBXW7β isoform 53 [15] . It has also been shown that PLK2-kinase dependent phosphorylation of 54 FBXW7 at S176 leads to its ubiquitin-mediated degradation and stabilization 55 of Cyclin E [16] . 56
Accurate spindle function is crucial for a successful mitosis. Perturbation of 57 ubiquitously expressed α-isoform of FBXW7 in mitotic HeLa cells at different 103 time points after induction of mitotic arrest. We observed a slow but gradual 104 decrease in the amount of FBXW7 protein during prolonged mitotic arrest 105 ( Figure 1A) . The dynamics of this decrease was similar to the decay of two 106 other regulators of mitotic cell fate, Cyclin B1 and MCL-1 [18] [30] . Moreover, 107 the decay of FBXW7, Cyclin B1 and MCL-1 was prevented by the addition of 108 the proteasomal inhibitor MG132 ( Figure 1B) . We therefore anticipated that 109 FBXW7 protein levels could be decreased in response to proteasomal protein 110 degradation. To identify proteins that regulate SCF-FBXW7 protein levels we 111 made use of an unbiased screen where we aimed at identifying FBXW7 112 binding proteins. We expressed Flag-FBXW7α in HEK-293T cells, FBXW7α 113 complexes were immunoprecipitated and subsequent mass spectrometrical 114 analysis was performed. Among the identified peptides were sequences 115 corresponding to FBXO45 and MYCBP2, along with SCF components and 116 known substrates of FBXW7 including MYC, Notch1/2 and members of the 117 mediator complex ( Figure 1C , Table S1 ). Interestingly, FBXO45 and MYCBP2 118 have previously been identified in other screens for FBXW7 interacting 119 proteins [31] [32] . They have also been described to form an SCF-like E3 120 ubiquitin ligase complex [33] . We therefore analyzed whether FBXO45-121 MYCBP2 is the ubiquitin ligase that regulates FBXW7 protein levels under 122 prolonged mitotic arrest. 123
124
The FBXO45-MYCBP2 complex binds to a conserved N-terminal motif in 125 perform most FBXW7 functions [2] . To identify the binding site of FBXO45 137 within FBXW7 we generated different FBXW7α truncated versions and found 138 that aa106-126 in the N-terminal domain of FBXW7α were required for 139 FBXO45 binding . Co-immunoprecipitation experiments 140 using full-length Flag-FBXW7α or a Flag-FBXW7αΔ106-126 mutant showed 141 that FBXW7αΔ106-126 failed to bind FBXO45 and MYCBP2 ( Figure 2C ). This 142 could be confirmed by the fact that FBXO45 only interacted with FBXW7α but 143 not with the other two isoforms, FBXW7β or FBXW7γ ( Figure EV1E ), that lack 144 the FBXW7α-specific N-terminal domain [34] again suggesting FBXW7α 145 specifically binds FBXO45. Interestingly, the N-terminal stretch within the 146 FBXW7α isoform (aa106-126) harbors conserved acidic amino acid residues 147 as a potential FBXO45 interaction domain ( Figure 2D ). On the other hand, we 148 identified the central domain of MYCBP2 (aa1951-2950) to be responsible for 149
FBXW7α binding ( Figures EV2A-B ). As this domain also contains the 150 FBXO45 interaction site of MYCBP2, we hypothesized that FBXO45 could be 151 the direct interaction partner of FBXW7α within the FBXO45-MYCBP2 152 complex. Analysis of binding between purified MBP-tagged N-terminal domain 153 of FBXW7α (MBP-FBXW7α-N167) and in vitro translated [ 35 S]-FBXO45 or 154 showed that FBXW7α directly binds to FBXO45 155 but not to MYCBP2 ( Figure 2E ). Furthermore, using sequential co-156 immunoprecipitation experiments we showed that FBXW7α exists in a 157 complex with FBXO45 and MYCBP2 ( Figure 2F ). 158
For some but not all F-box proteins it has been demonstrated that 159 phosphorylation of their specific substrates is required for binding [35] . We 160 have previously shown that phosphorylation of FBXW7 by PLK2 leads to 161 destabilization of the F-box protein [16] . However, as shown in Figure EV2C , 162 inhibition of PLK2 by the small molecule inhibitor BI2536 that targets both 163 PLK1 and PLK2 kinases did not impair the binding between FBXO45 and 164 FBXW7. Moreover, overexpression of GFP-PLK2 did not promote the 165 interaction ( Figure EV2D ). Our data therefore suggest that the FBXW7α-166 FBXO45 interaction is independent of phosphorylation by PLK2. 167
Together, these results show that the FBXO45-MYCBP2 complex interacts 168 with a conserved acidic stretch within the N-terminal domain of FBXW7α. 169 170 FBXO45-MYCBP2 targets FBXW7α for degradation specifically during 171
mitotic arrest 172
As FBXW7α is predominantly found in the nucleus [36] whereas FBXO45 and 173 MYCBP2 are cytosolic proteins [25] [37] ( Figure 3A ), a possible interaction 174 between these proteins may occur in mitosis upon nuclear envelope 175 breakdown, when the contents of the cell nucleus are released into the 176 cytoplasm. As FBXO45 is likely to be the substrate binding factor we analyzed 177 the interaction between Flag-FBXO45 and endogenous FBXW7α in 178 asynchronous and mitotic HeLa cells. We specifically prepared the cell 179 extracts for the experiment shown in Figure 3B under conditions where the 180 nucleus remains intact in asynchronous cells. Interestingly, FBXW7α was 181 specifically found in co-immunoprecipitation with Flag-FBXO45 in mitotic cells 182 ( Figure 3B ). Furthermore, we noticed an increase in FBXW7α protein levels 183 upon siRNA-mediated downregulation of FBXO45. This effect could only be 184 observed in cells under a prolonged mitotic arrest but not in cells passing 185 through an unperturbed mitosis. In addition, the effect was not observed in 186 asynchronous cells ( Figures 3C and EV3A-B ). On the other hand, FBXW7 187 downregulation had no effect on FBXO45 protein levels ( Figure 3C ). To 188 exclude off-target effects we used different FBXO45 and MYCBP2 siRNAs to 189 reduce their expression in HeLa cells and confirmed that FBXW7α protein 190 levels were upregulated in cells that were FBXO45 or MYCBP2-depleted 191 under prolonged mitotic arrest ( Figure EV3C ). The effect could be confirmed 192 in U2OS cells using nocodazole and in HeLa cells using different inhibitors 193 that cause a mitotic arrest (Figures EV3D-I). We also aimed to confirm the 194 observed regulation of FBXW7α protein levels by expression of a dominant-195 negative MYCBP2(1951-2950) fragment that binds FBXO45 and FBXW7α but 196 lacks the RING domain ( Figures EV2A-B ). Upon ectopical expression of Flag-197 MYCBP2(1951 -2950 we found that FBXW7α protein levels were specifically 198 upregulated in mitotic cells after treatment with nocodazole ( Figure 3D ). 199
Taken together, FBXO45 binds FBXW7α in mitotic cells and the FBXO45- 
FBXO45-MYCBP2 targets FBXW7α for ubiquitylation and degradation 205
To find out whether the regulation of FBXW7α by FBXO45-MYCBP2 is 206 mediated by ubiquitylation we carried out in vivo ubiquitylation assays. We 207 found that both overexpression of FBXO45 and MYCBP2 promote 208 ubiquitylation of FBXW7α ( Figure 4A ). Deletion of the FBXO45 binding site in 209
FBXW7α reduced the ubiquitylation of FBXW7α markedly in in vivo 210 ubiquitylation assays using FBXW7αΔ106-126 expression ( Figure 4B ). To 211 study the effect of FBXO45 on FBXW7α protein stability, we depleted 212 FBXO45 in nocodazole-treated cells and added cycloheximide to block 213 translation. Cells were then harvested at different time points after 214 cycloheximide addition. In FBXO45-depleted cells FBXW7α was markedly 215 stabilized ( Figure 4C ) suggesting that FBXO45 promotes degradation of 216
FBXW7α upon mitotic arrest. In addition, Flag-FBXW7αΔ106-126 was 217 stabilized in comparison to full-length Flag-FBXW7α. The stability of Flag-218
FBXW7α was increased by MG132 treatment ( Figure 4D ). From these 219 experiments, we conclude that FBXO45-MYCBP2 mediated degradation of 220
FBXW7α during prolonged mitosis depends on the proteasome. 221
222

FBXO45-MYCBP2 reduces the sensitivity of cells to spindle poisons 223
Previous studies have shown that FBXW7 regulates mitotic cell fate. In fact, 224 FBXW7 promotes mitotic cell death and prevents mitotic slippage in cells that 225 have been treated with anti-microtubule drugs to arrest them in mitosis [21] 226 [22] , which is in line with its function as a tumor suppressor. As we had found 227 that FBXO45-MYCBP2 regulates FBXW7α protein levels during mitotic arrest 228 ( Figure 3) , we asked whether the FBXO45-MYCBP2 complex as a regulator 229 of FBXW7 would also affect mitotic cell fate. To test this, we analyzed mitotic 230 cell fate by live-cell imaging ( Figure 5A , Video S1-2). For our live-cell imaging 231 analysis, we treated the cells with spindle poisons at concentrations that 232 completely prevented cell division and caused either mitotic cell death or 233 mitotic slippage [38] . As shown in Figure 5B , reduction of FBXO45 led to an 234 increase in mitotic cell death in cells that were arrested in mitosis with 235 nocodazole. Similar effects were observed in cells arrested in mitosis by Taxol 236 or vincristine treatment ( Figures EV4A-B ). To exclude off-target effects we 237 used siRNAs targeting different regions of FBXO45 mRNA ( Figure 5B ). In 238 addition, expression of an siRNA-resistant version of Flag-FBXO45 was able 239 to rescue the effect on mitotic cell fate ( Figure 5C ). Moreover, siRNA-240 mediated downregulation of MYCBP2 also caused an increase in mitotic cell 241 death ( Figure EV4C ). In contrast, FBXO45 and MYCBP2 depletion did not 242 have an effect on progression of cells through an unperturbed mitosis ( Figure  243 EV4D). To verify the results in an siRNA independent approach, we analyzed 244 the effect of the dominant-negative MYCBP2(1951-2950) fragment on mitotic 245 cell fate. As expected, overexpression of Flag-MYCBP2(1951-2950) 246 increased mitotic cell death ( Figure 5D ). Taken together, our results showed 247 that the FBXO45-MYCBP2 complex negatively regulates mitotic cell death 248 and increases mitotic slippage, suggesting that it has an opposing function 249 during mitotic arrest compared to FBXW7. This is in line with the FBXO45-250 MYCBP2 complex being a negative regulator of FBXW7α during mitotic 251 arrest. We therefore asked whether the observed effect of FBXO45-MYCBP2 252 on mitotic cell fate depends on FBXW7. In fact, FBXW7 depletion was able to 253 rescue the effect of FBXO45, suggesting that FBXW7 is the downstream 254 target of the FBXO45-MYCBP2 complex that mediates mitotic cell fate 255 regulation ( Figure 5E ). Together, our data strongly suggest that FBXO45-256 MYCBP2-mediated degradation of FBXW7 under prolonged mitotic arrest 257 induces mitotic slippage and prevents mitotic cell death. 258
Prolonged mitotic arrest is caused by a sustained activation of the spindle 259 assembly checkpoint (SAC). If the SAC cannot be satisfied and mitosis 260 cannot be completed, there are two alternative cell fates. Cells either undergo 261 mitotic cell death or perform mitotic slippage. Cell fate following mitotic arrest 262 is regulated by two competing networks, namely Cyclin B1 degradation and 263 pro-apoptotic caspase activation [39] . Besides cell fate regulation through 264 Cyclin B1, MCL-1, a pro-survival member of the BCL-2 family, was shown to 265 be involved in cell fate decision. MCL-1 is degraded by a ubiquitin-266 proteasome-dependent mechanism in response to the disruption of mitosis, 267 resulting in cell death [39] [30] [22] . 268
The tumor suppressor FBXW7 also plays important roles in mitotic cell fate 269 [42] . Therefore, it could be meaningful to further characterize 278 FBXO45 as a putative oncoprotein in future studies. MYCBP2 has been 279 recently uncovered as a novel type of E3 ligase with esterification activity 280 leading to ubiquitylation of serine and threonine residues in substrates [43] , 281 which is intrinsic to higher eukaryotes. In the future, it would therefore be 282
interesting to see whether FBXW7 could be ubiquitylated on hydroxyl groups 283 by MYCBP2. 284
As FBXW7α is a nuclear protein but FBXO45 is found in the cytoplasm 285 ( Figure 3A ), the two proteins can only interact upon nuclear envelope 286 breakdown ( Figure 3B ). However, since mitosis is a relatively short process in 287 the eukaryotic cell cycle, the successful formation of a sustained interaction 288 between FBXO45 and FBXW7α as well as FBXW7α ubiquitylation may 289 require a longer arrest in mitosis. Interestingly, the degradation of two other 290 regulators of mitotic cell fate, MCL-1 and Cyclin B1, has also been shown to 291 occur in a slow and gradual manner during mitotic arrest [18] [30] . 292
In the future, the development of a specific inhibitor to block the FBXO45-293 MYCBP2-FBXW7α axis might actively promote mitotic cell death and prevent 294 mitotic slippage. Therefore, treatment of cancer patients with this inhibitor 295 after or in combination with anti-microtubule drugs could be a promising 296 approach in order to increase the efficiency of chemotherapeutic treatment. 297
298
MATERIALS AND METHODS 299 300
Cell culture and transfection 301
Human cell lines were grown in a humidified atmosphere with 5% CO2 at 302
37°C. HeLa, U2OS and U2OS Flp-In-T-Rex cells were cultured in Dulbecco's 303
Modified Eagle's Medium (DMEM, Sigma-Aldrich) with 1 g/l glucose. HEK-304
293T cells were grown in DMEM with 4.5 g/l glucose. The media were 305 supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich or Thermo 306 Scientific). HeLa GFP-α-tubulin/RFP-H2B cells (D. Gerlich, ETH Zürich) were 307 cultured in DMEM containing 1 g/l glucose, 10% FBS, 500 µg/ml G418 and 308 0.5 µg/ml puromycin. The T-Rex system was used to generate U2OS Flp-In-309 In order to arrest HeLa or U2OS cells in G1/S phase, the cells were treated 337 with 2 mM thymidine for 18 h. In order to arrest HeLa or U2OS cells in mitosis, 338 cells were first synchronized in G1/S phase by treatment with 2 mM thymidine 339 for 17 h. The cells were released into the cell cycle by washing three times 340 with PBS and incubation with fresh growth medium for 5 h. Finally, the cells 341 were treated with 250 ng/ml nocodazole, 500-1000 nM Taxol, 500 nM 342 vincristine, 5 µM STLC or 100 nM BI2536 for 16-17 h. Mitotic cells were 343 collected by a mitotic shake-off. 344
345
MG132 and cycloheximide treatment 346
In order to inhibit proteasomal degradation in HEK-293T cells, the cells were 347 treated with 10 µM MG132 (Sigma-Aldrich) for 4-5 h before harvesting. In 348 order to inhibit protein synthesis in HeLa cells, they were treated with 349 100 µg/ml cycloheximide (Sigma-Aldrich). For a cycloheximide chase assay, 350 the cells were harvested at different time points after cycloheximide treatment. Observer Z1 inverted microscope (AxioCam MRm camera system) with 361 incubation at 5% CO2 and 37°C. Multi-tile phase-contrast images were taken 362 every 10 min for 48 h using the Zeiss ZEN blue software. Data analysis was 363 performed with ImageJ Fiji software. Cell death was defined by cell 364 morphology and cessation of movement. Mitotic slippage was defined by 365 mitotic exit without cell division. For the analysis of unperturbed mitotic 366 progression, HeLa GFP-α-tubulin/RFP-H2B cells were transfected with 30 nM 367 siRNA targeting GL2 or FBXO45 and MYCBP2. Analysis was performed as 368 described previously [44] . 48 h after transfection, 2.5 x 10 4 cells were seeded 369 into Ibidi dish chambers and arrested in G1/S phase by thymidine treatment. 370 24 h after thymidine addition, the cells were released from the arrest and 371 analyzed by live-cell imaging using LED module Colibri.2 with 470 nm for GFP 372 and 590 nm for RFP fluorochrome excitation. 373
Preparation of protein extracts from mammalian cells 375
For the preparation of cell extracts, cell pellets were resuspended in 3-5 376 volumes of RIPA, NP40 or Urea lysis buffer. RIPA lysis buffer (50 mM Tris-377 HCl pH 7.4, 1% NP40, 0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 378 2 mM EDTA, 50 mM NaF, 1 mM DTT, 10 µg/ml TPCK, 5 µg/ml TLCK, 0.1 mM 379 Na3VO4, 1 µg/ml Aprotinin, 1 µg/ml Leupeptin, 10 µg/ml Trypsin inhibitor from 380 soybean) was used for the analysis of protein levels in whole cell extracts and 381
for in vivo ubiquitylation assays. NP40 lysis buffer (40 mM Tris-HCl pH 7.5, 382 150 mM NaCl, 5 mM EDTA, 10 mM β-glycerophosphate, 5 mM NaF, 0.5% 383 NP40, 1 mM DTT, 10 µg/ml TPCK, 5 µg/ml TLCK, 0.1 mM Na3VO4, 1 µg/ml 384 Aprotinin, 1 µg/ml Leupeptin, 10 µg/ml Trypsin inhibitor from soybean) was 385 used for immunoprecipitations. Urea lysis buffer (8 M Urea, 30 mM imidazole, 386 0.1 M phosphate buffer pH 8.0) was used for in vivo ubiquitylation assays. 387
The cell lysates were incubated on ice for 30 min with short vortexing every 5-388 10 min. The lysates were cleared by centrifugation at maximal speed and 4°C 389 in an Eppendorf 5415 R centrifuge for 15 min. The supernatants were 390 transferred to fresh reaction tubes. Extracts of cytoplasmic and nuclear cell 391 fractions were prepared using the CelLytic NuCLEAR Extraction Kit (Sigma) 392
according to the manufacturer's instructions. 393
The protein concentration of a cell extract was determined according to the 394 Bradford method in a Bio-Rad Protein assay. For SDS-PAGE, the cell extracts 395
were mixed with equal volumes of 2x Laemmli buffer and incubated at 95°C 396 for 5 min. 397 398
Western blotting 399
The following antibodies were used for Western blotting: Rabbit α-FBXW7α 400 antibody (A301-720A, 1:15000) was obtained from Bethyl. Rabbit α-FBXO45 401 (NBP1-91891, 1:500) was purchased from Novus. Rabbit α-MYCBP2 was a 402 kind gift from K. Scholich [45] . Mouse α-Flag (M2, F3165, 1:5000), mouse α-403 tubulin (B-5-1-2, 1:10000) and mouse α-Vinculin (hVIN-1, 1:5000) were 404 obtained from Sigma-Aldrich. Rabbit α-Cyclin B1 has been described before 405 Analysis Facility, Heidelberg). Briefly, whole gel lanes were cut into slices. 448
Proteins were reduced and alkylated by incubation with 10 mM DTT in 40 mM 449 NH4HCO3 for 1 h at 56°C in the dark and incubation with 55 mM 450 iodoacetamide in 40 mM NH4HCO3 for 30 min at 25°C. After washing of the 451 slices with H2O and 50% acetonitrile, they were dried with 100% acetonitrile. 452
Proteins were digested in-gel with trypsin (0.17 µg in 10 µl 40 mM NH4HCO3, 453 Promega) at 37°C over night. Tryptic peptides were extracted with 50% 454 acetonitrile/0.1% TFA and 100% acetonitrile. Supernatants were lyophilized 455 and redissolved in 0.1% TFA/5% hexafluoroisopropanol. Solutions were 456 analyzed by nanoLC-ESI-MS/MS. Peptides were separated with a 457 nanoAcquity UPLC system (Waters GmbH). Peptides were loaded on a C18 458 trap column with a particle size of 5 µm (Waters GmbH). Liquid 459 chromatography was carried out on a BEH130 C18 column with a particle size 460 of 1.7 µm (Waters GmbH). A 1 h gradient was applied for protein 461 identification. The nanoUPLC system was connected to an LTQ Orbitrap XL 462 mass spectrometer (Thermo Scientific). Data were acquired with the Xcalibur 463 Bacteria were harvested by centrifugation at 5000 rpm and 4°C for 15 min 504 (F10-6x500Y rotor, Piramoon). The pellet was resuspended in 25 ml of cold 505 column buffer. Cell lysis was performed with a high pressure homogenizer 506 (15000-17000 psi/1030-1170 bar for one pass, EmulsiFlex C5, Avestin). The 507 lysate was centrifuged at 20000 g and 4°C for 20 min (WX Ultra 80, Thermo 508 Scientific). The supernatant was applied onto a column with 1 ml of 509 equilibrated amylose resin (NEB). The column with the beads and the extract 510 was incubated on a rotating wheel at 4°C for 1 h. Afterwards, the beads were 511 washed three times with 15 ml of column buffer. Finally, the proteins bound to 512 the beads were eluted with 5 ml of column buffer containing 10 mM maltose. 
In vitro transcription and translation and in vitro binding assays 523
For in vitro binding assays, FBXO45 and MYCBP2(1951-2950) Selection of proteins that were specifically identified in co-immunoprecipitation 861 with Flag-FBXW7α. For each protein, the MASCOT score, mass, number of 862 significant sequences and coverage are specified. 
